Legend Biotech Earnings Reports

Legend Biotech saw revenue more than double year-over-year in Q1 2025 due to strong CARVYKTI-related collaboration revenue. However, operating expenses and foreign exchange losses led to a larger net loss. The company remains confident in achieving profitability by 2026.

Legend Biotech reported Q4 2024 revenue of $186.5 million, significantly increasing from $79.5 million in Q4 2023. The company posted a net income of $26.3 million, reversing a prior-year net loss of $144.8 million. EPS was $0.07, while adjusted EPS was -$0.16. The results reflect strong CARVYKTI sales and licensing revenue growth.